Navigation Links
Mylan Announces Final FDA Approval for Carvedilol Tablets
Date:9/6/2007

PITTSBURGH, Sept. 6 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Carvedilol Tablets, 3.125 mg, 6.25 mg, 12.5 mg and 25 mg.

Carvedilol Tablets are the generic version of GlaxoSmithKline's Coreg(R) Tablets. Carvedilol Tablets had U.S. sales of approximately $1.65 billion for the 12 months ending June 30, 2007, for the same strengths.

This product has shipped.

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc., and a controlling interest in Matrix Laboratories Limited, India. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products.

For more information about Mylan, please visit http://www.mylan.com.


'/>"/>
SOURCE Mylan Laboratories Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Mylan Wins Its Amlodipine Case With Pfizer
2. Mylan Announces Tentative FDA Approval for Its ANDA
3. Mylan Announces Final FDA Approval for Fluoxetine Capsules
4. PM announces a new health care order for India
5. PowderMed Announces Needle-Less Flu Vaccine
6. Ramdoss Announces Introduction of RCH-II
7. Britain Announces Third Transfusion Related Mad Cow Case
8. Tibet Announces the Dalai Lama’s Tour of South Americ
9. NHS announces further Cost cutting Measures
10. Indian PM Announces Of Setting Up India Study Center At Tashkent
11. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)...re/ -- A special supplement of the Oct. 15,journal...low- and,middle-income countries to implement brea...mmon disease among women worldwide., "Guidelines ... -,Implementation" developed by the Breast Health ...of resource allocation -- based on countries,over...
(Date:10/6/2008)...RNewswire/ -- Ohio,s academic health care,industry...in 2007, an,increase of approximately $16.5 billio... employing one in 12 Ohioans, according to a recen...l Deans., Quantifying academic medicine,s economi...creation, the report underscores the significant r...
(Date:10/6/2008)... Candice Lane, a leading physician in anti-aging m...ging, and aesthetic blog, Hormone Health MD Plus, ...n not widely availabe among practicing physicians....enopause, menopause, PMS, andropause, thyroid defi...and fatigue, and diseases of aging using bioidenti...
(Date:10/6/2008)...gram offers up to 50 percent savings on medical se... Belleville, Ill. (Vocus) October 6, 2008 ...p://www.allsup.com/Health-Discount-Program.aspx/?=...count Program] to help millions of people with dis... medical services. The program is among the new fi...
Breaking Medicine News(10 mins):Health News:International Implementation of Breast Health Guidelines for Developing Countries Published by Cancer 2Health News:International Implementation of Breast Health Guidelines for Developing Countries Published by Cancer 3Health News:Academic Medicine Means Business for Ohio: $37.2 Billion Economic Impact for the State 2Health News:Candice Lane MD Launches Hormone Health MD Plus: The First Doctor Bioidentical Hormone Blog 2Health News:Candice Lane MD Launches Hormone Health MD Plus: The First Doctor Bioidentical Hormone Blog 3Health News:Allsup Introduces Health Discount Program to Millions of People with Disabilities 2Health News:Allsup Introduces Health Discount Program to Millions of People with Disabilities 3
...uits and vegetables can pave way for a long and he...ch has pointed out that fruits and vegetables can ... medicines. Foods can // increase or decrease the ...stered drugs. The effect does not hold good for dr...
...rom World Health Organization (WHO), shows that 36...iseases such as heart diseases, stroke, cancer and...prevent this // in the next 10 years. The main fac...iseases is Tobacco, poor diet, in sufficient exerc...
...psy Foundation has urged women of childbearing age...s that include epilepsy, migraine headaches, and c...lthcare // providers about treatment options. Near...oin the cause towards reducing anti-convulsant med...
...which is used in the treatment of Multiple Scleros...two patients taking the drug complained of neurolo... and // Progressive Multifocal Leukoencephalopathy...the drug is deemed to pose a significant risk, it ...
Other Medicine News:Health News:A call to epileptic mothers to help reduce birth defects 2
(Date:10/6/2008)...E, Oct. 6 /- Dendreon Corpo...today, Monday, October 6, 2008 at 9:00 AM,ET (6:00...sis of its IMPACT,(IMmunotherapy for Prostate Aden...al trial of PROVENGE(R) (sipuleucel-T), the Compan...for the treatment of advanced prostate,cancer., ...
(Date:10/3/2008)...DAM, October 3 /- Amsterdam...in the field of human gene therapy,announced toda...nto the,Marketing Authorization Application (MAA) ...LPLD), a seriously debilitating and potentially le...phase II clinical studies (22,patients in total) d...
(Date:10/2/2008)...Robert Weiss, Director of Maryland Laser, Skin and...ctice -, BALTIMORE, Oct. 2 /- Robert...ong the first physicians in the U.S. to offer his,... the latest,state-of-the-art procedure in laser s...enowned dermatologist, who is in private practice ...
(Date:10/2/2008)... Indicate Dual Modes of Action and Synergy with Ch... -- Access Pharmaceuticals, Inc.,(OTC Bulletin Boa...l,studies on Angiolix showing that by blocking lac...ect as well as a direct anti-proliferative effect ...an breast cancer (MX-1),Angiolix had a significan...
Breaking Medicine Technology:Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 2AMT Intends to Incorporate Additional Data to its Marketing Authorization Dossier for Glybera(R) 2AMT Intends to Incorporate Additional Data to its Marketing Authorization Dossier for Glybera(R) 3DOT Therapy: Newest Breakthrough Technology in Laser Skin Resurfacing 2Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody 2Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody 3Milton Frank Appointed COO of Life Recovery Systems 23589 1Milton Frank Appointed COO of Life Recovery Systems 23589 2Pennsylvania Governor Rendell Signs Bill Ensuring Continuity of Care for Children Young Adults with Autism 23585 1Pennsylvania Governor Rendell Signs Bill Ensuring Continuity of Care for Children Young Adults with Autism 23585 2Depression after stroke 3A A neglected problem 23583 1Depression after stroke 3A A neglected problem 23583 2Depression after stroke 3A A neglected problem 23583 3Aerosol toxins from red tides may cause long term health threat 3962 1Aerosol toxins from red tides may cause long term health threat 3962 2
...4, 2007 - Cytos,Biotechnology AG (SWX:CYTN) report...-blind combined phase I/IIa study with,CYT007-TNFQ...psoriasis and other inflammatory conditions. The p...l and included 48 patients,suffering from moderate...e study, the safety and tolerability of ascending ...
... Biotechnology Corporation,(NasdaqCM:GNBT) announc...nobiology at its wholly-owned Antigen Express subs...t strategy at an,international conference in Londo...Anti-Infective Agents - Challenges and,Opportuniti...ectives-forum.com">www.anti-infectives-forum.com )...
Other Medicine Technology:Cytos Reports Results from Phase I/IIa Study with CYT007-TNFQb for,the Treatment of Psoriasis 2Cytos Reports Results from Phase I/IIa Study with CYT007-TNFQb for,the Treatment of Psoriasis 3Cytos Reports Results from Phase I/IIa Study with CYT007-TNFQb for,the Treatment of Psoriasis 4Generex Biotechnology Vaccine Strategy Presented at International,Conference in London 2Generex Biotechnology Vaccine Strategy Presented at International,Conference in London 3
A finely parallel striated (scratched) clear plastic membrane encapsulated between glass plates.
Bagolini's striated lenses consists of 2 circular lenses in a metal frame with tabs for use by the examiner.
BD Visitec IOL Manipulator, blunt tip, formed 10.0mm from end. Fits 0.20mm diameter holes & larger (3/bx, 1 bx/ca). For positioning intraocular lenses. Sure grip handles hand ridge indicating positio
BD Visitec™ button tip manipulator, 0.50 mm diameter button tip angled 45, 15.0 mm from end (3/bx, 1 bx/ca). May be used for IOL manipulation or iris retraction. Sterile.
Medicine Products: